Диссертация (1140142), страница 19
Текст из файла (страница 19)
‒ 1970. ‒ Vol. 140, № 3. ‒ P. 195206.176. Kapoor R., Phiske M.M., Jerajani H.R. Evaluation of safety andefficacy of topical prostaglandin E2 in treatment of vitiligo // Br J Dermatol. ‒2009. ‒ Vol. 160, № 4. ‒ P. 861-3.118177. Karimipour D.J., Rittie L., Hammerberg C et al. Molecular analysis ofaggressive microdermabrasion in photoaged skin // Arch.
Dermatol. - 2009. Vol.145. - P. 1114–1122.178. Karsli N., Akcali C., Ozgoztasi O. et al. Role of oxidative stress in thepathogenesis of vitiligo with special emphasis on the antioxidant action ofnarrowband ultraviolet B phototherapy // J. Int. Med. Res. - 2014.
- Vol.42 (3). P.799-805.179. Kaux J.F., Le Goff C., Seidel L. et al. Comparative study of fivetechniques of preparation of platelet –rich plasma // Pathol. Biol. - 2011. - Vol. 59.- P. 157–160.180. Kim D.Y., Lee J.W., Whang S.H. et al. Quality of life for Koreanpatients with vitiligo: Skindex-29 and its correlation with clinical profiles // JDermatol. ‒ 2009. ‒ Vol. 36, № 6. ‒ P. 317-322.181. Kim J.Y., Kim do Y., Son H. et al. Protease-activated receptor-2activates NQO-1 via Nrf2 stabilization in keratinocytes // J. Dermatol. Sci.- 2014.- Vol.74(1). - P.48-55.182. Kim N.H., Torchia D., Rouhani P. et al. Tumor necrosis factor-alphain vitiligo: direct correlation between tissue levels and clinical parameters // Cutan.Ocul.
Toxicol. ‒ 2011. ‒ Vol. 30, № 3. ‒ P. 225-227.183. Kim Y.C., Kim Y.J., Kang H.Y. et al. Histopathologic features invitiligo // Am. J. Dermatopathol. ‒ 2008. ‒ Vol. 30, № 2. ‒ P. 112-116.184. Kim W.S., Park B.S., Park S.H. et al. Anti-wrinkle effect of adiposederived stem cell: activation of dermal fibroblast by secretory factors // J.Dermatol. Sci. - 2009. - Vol.53. - P.
96 –102.185. Kingo K., Reimann E., Karelson M. et al. Association analysis ofgenes of the IL19 cluster and their receptors in vitiligo patients // Dermatology. 2010. - Vol.221(3). - P.261-266.186. Kingo K., Aunin E., Karelson M. et al. Expressional changes in theintracellular melanogenesis pathways and their possible role in the pathogenesis ofvitiligo // J. Dermatol.
Sci. - 2008. - Vol.52(1). - P.39-46.119187. Kitamura R., Tsukamoto K., Harada K. et al. Mechanisms underlyingthe dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT proteininteractions and the downstream effector. MITF-M // J. Pathol. -2004. -Vol.202(4).- P.463-475.188. Knezevic N.N., Candido K.D., Desai R., Kaye A.D. Is Platelet-RichPlasma a Future Therapy in Pain Management? // Med. Clin. North.
Am. ‒ 2016. ‒Vol. 100, № 1. ‒ P. 199-217.189. Ko W.C., Chen Y.F. Suction blister epidermal grafts combined withCO2 laser superficial ablation as a good method for treating small-sized vitiligo //Dermatol. Surg. ‒ 2009. ‒ Vol. 35, № 4. ‒ P. 601-606.190. Korobko I.V., Lomonosov K.M. A pilot comparative study of topicallatanoprost and tacrolimus in combination with narrow-band ultraviolet Bphototherapy and microneedling for the treatment of nonsegmental vitiligo //Dermatol Ther.
‒ 2016. ‒ Vol. 29, № 6. ‒ P. 437-441.191. Kota R.S., Vora R.V., Varma J.R. et al. Study on Assessment ofQuality of Life and Depression in Patients of Vitiligo // Indian Dermatol Online J.- 2019. - Vol.10(2). - P.153-157.192. Kotb El-Sayed M.I., Abd El-Ghany A.A., Mohamed R.R. Neural andEndocrinal Pathobiochemistry of Vitiligo: Comparative Study for a HypothesizedMechanism // Front Endocrinol (Lausanne).- 2018. - Vol.9:197. doi:10.3389/fendo.2018.00197.193. Krishnan A., Kar S. Smashed skin grafting or smash grafting - a novelmethod of vitiligo surgery // Int. J.
Dermatol. ‒ 2012. ‒ Vol. 51, № 10. ‒ P. 12421247.194. Kroll T.M., Bommiasamy H., Boissy R.E. et al. 4-Tertiary butylphenol exposure sensitizes human melanocytes to dendritic cell-mediated killing:relevance to vitiligo // J. Invest. Dermatol. ‒ 2005.
‒ Vol. 124, № 4. ‒ P. 798-806.195. Kundu R.V., Mhlaba J.M., Rangel S.M., Le Poole I.C. Theconvergence theory for vitiligo: A reappraisal // Exp Dermatol. - 2018. - Apr 28.[Epub ahead of print].120196. Kyriakis K.P., Palamaras I., Tsele E. et al. Case detection rates ofvitiligo by gender and age // Int. J. Dermatol. ‒ 2009. ‒ Vol. 48, № 3. ‒ P. 328-329.197. Le Poole I.C., Das P.K., van den Wijngaard R.M. et al. Review of theetiopathomechanism of vitiligo: a convergence theory // Exp.
Dermatol. ‒ 1993. ‒Vol. 2, № 4. ‒ P. 145-153.198. Lee A.Y., Kim N.H., Choi W.I. et al. Less keratinocyte-derivedfactors related to more keratinocyte apoptosis in depigmented than normallypigmented suction-blistered epidermis may cause passive melanocyte death invitiligo // J. Invest. Dermatol. - 2005. - Vol.124 (5). - P.976-983.199. Lee A.Y. Role of keratinocytes in the development of vitiligo // Ann.Dermatol. - 2012. - Vol.24(2). - P.115-125.200. Lee H.S., Goh M.J., Kim J. et al.
A systems-biological study on theidentification of safe and effective molecular targets for the reduction of ultravioletB-induced skin pigmentation // Sci Rep. - 2015. - Vol.5. - P.10305201. Lee J., Chu H., Lee H. et al. A Retrospective Study ofMethylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB inNon-Segmental Vitiligo // Dermatology. ‒ 2016. ‒ Vol. 232, № 2. ‒ P.
224-229.202. Lei T.C., Vieira W.D., Hearing V.J. In vitro migration of melanoblastsrequires matrix metalloproteinase-2: implications to vitiligo therapy byphotochemotherapy // Pigment Cell. Res. ‒ 2002. ‒ Vol. 15, № 6. ‒ P. 426-432.203. Leone G., Paro Vidolin A.
Effect of an antioxydant cream versusplacebo in patients with vitiligo in association with excimer laser. A pilotrandomized, investigator-blinded, and half-side comparison trial // G. Ital.Dermatol. Venereol. ‒ 2015. ‒ Vol. 150, № 4. ‒ P. 461-466.204. Lepe V., Moncada B., Castanedo-Cazares J.P. et al. A double-blindrandomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment ofchildhood vitiligo // Arch.
Dermatol. ‒ 2003. ‒ Vol. 139, № 5. ‒ P. 581-585.205. Levandowski C.B., Mailloux C.M., Ferrara T.M. et al. NLRP1haplotypes associated with vitiligo and autoimmunity increase interleukin-1betaprocessing via the NLRP1 inflammasome // Proc. Natl. Acad. Sci. USA. ‒ 2013. ‒121Vol. 110, № 8. ‒ P. 2952-2956.206. Li P., Ma H., Han D.
et al. Interleukin-33 affects cytokine productionby keratinocytes in vitiligo // Clin. Exp. Dermatol. - 2015. - Vol.40(2). - P.163170.207. Liang L., Li Y., Tian X. et al. Comprehensive lipidomic, metabolomicand proteomic profiling reveals the role of immune system in vitiligo // Clin ExpDermatol. - 2019. - Mar 12. doi: 10.1111/ced.13961. [Epub ahead of print]208. Lim H.K., Sh M.K., Lee M.H. Clinical application of PRP in vitiligo:a pilot study. Official 1st International Pigment Cell Conference, 2011.209. Linthorst Homan M.W., Spuls P.I., de Korte J.
et al. The burden ofvitiligo: patient characteristics associated with quality of life // J. Am. Acad.Dermatol. ‒ 2009. ‒ Vol. 61, № 3. ‒ P. 411-420.210. Lippross S., Moeller B., Haas H. et al. Intraarticular injection ofplatelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis ofthe knee joint // Arthritis Rheum. ‒ 2011. ‒ Vol. 63, № 11. ‒ P. 3344-3353.211.
Lotti T., D’Erme A.M. Vitiligo as a systemic disease // Clin.Dermatol. - 2014. - Vol.32 (3). - P.430-434.212. Lotti T., Buggiani G., Troiano M. et al. Targeted and combinationtreatments for vitiligo. Comparative evaluation of different current modalities in458 subjects // Dermatol. Ther. ‒ 2008. ‒ Vol. 21 Suppl 1. ‒ P. S20-26.213. Lotti T., Hercogova J., Wollina U. et al. Vitiligo: successfulcombination treatment based on oral low dose cytokines and different topicaltreatments // J. Biol.
Regul. Homeost. Agents. - 2015. - Vol.29 (Suppl. 1). - P.5358.214. Lu T., Gao T., Wang A. et al. Vitiligo prevalence study in ShaanxiProvince, China // Int. J. Dermatol. ‒ 2007. ‒ Vol. 46, № 1. ‒ P. 47-51.215. Lucarelli E., Beretta R., Dozza B. et al. A recently developed bifacialplatelet-rich fibrin matrix // Eur. Cell Mater.
- 2010. - Vol. 20. - P.13 –23.216. Mapar M.A., Safarpour M., Mapar M., Haghighizadeh M.H. Acomparative study of the mini-punch grafting and hair follicle transplantation in122the treatment of refractory and stable vitiligo // J. Am.
Acad. Dermatol. ‒ 2014. ‒Vol. 70, № 4. ‒ P. 743-747.217. March L., Woolf A.D. The global burden of musculoskeletalconditions - why is it important? // Best Pract. Res. Clin. Rheumatol. ‒ 2010. ‒Vol. 24, № 6. ‒ P. 721.218. Marie J., Kovacs D., Pain C. et al. Inflammasome activation andvitiligo/ nonsegmental vitiligo progression // Br. J. Dermatol. - 2014. - Vol.170(4).- P.816-823.219. Marques L.F., Stessuk T., Camargo I.C. et al. Platelet-rich plasma(PRP): methodological aspects and clinical applications // Platelets.
‒ 2015. ‒ Vol.26, № 2. ‒ P. 101-113.220. Maruthappu T., Leandro M., Morris S.D. Deterioration of vitiligo andnew onset of halo naevi observed in two patients receiving adalimumab //Dermatol. Ther. ‒ 2013. ‒ Vol. 26, № 4. ‒ P. 370-2.221. Marx R.E. Platelet-rich plasma: evidence to support its use // J.
OralMaxillofac. Surg. ‒ 2004. ‒ Vol. 62, № 4. ‒ P. 489-496.222. Mattoo S.K., Handa S., Kaur I. et al. Psychiatric morbidity in vitiligo:prevalence and correlates in India // J. Eur. Acad. Dermatol. Venereol. ‒ 2002. ‒Vol. 16, № 6. ‒ P. 573-578.223. Maynard D.M., Heijnen H.F., Horne M.K.
et al. Proteomic analysis ofplatelet alpha-granules using mass spectrometry // J. Thromb. Haemost. ‒ 2007. ‒Vol. 5, № 9. ‒ P. 1945-1955.224. Mazzucco L., Balbo V., Cattana E. et al. Not every PRP-gel is bornequal. Evaluation of growth factor availability for tissues through four PRP-gelpreparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure // VoxSang. ‒ 2009. ‒ Vol. 97, № 2.
‒ P. 110-118.225. McGovern T.W., Bolognia J., Leffell D.J. Flip-top pigmenttransplantation: a novel transplantation procedure for the treatment ofdepigmentation // Arch. Dermatol. ‒ 1999. ‒ Vol. 135, № 11. ‒ P. 1305-1307.226. Meheux C.J., McCulloch P.C., Lintner D.M. et al. Efficacy of Intra-123articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A SystematicReview // Arthroscopy. ‒ 2016. ‒ Vol. 32, № 3. ‒ P. 495-505.227. Mei-Dan O., Lippi G., Sanchez M. et al. Autologous plateletrichplasma: arevolution in soft tissue sports injury management? // Phys Sportsmed. 2010. - Vol. 38. -P. 127–135.228.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
